This week's pharmaceutical changes begin with the election of Reuters' head to the Board of Pfizer.
Pfizer has elected the President and CEO of media giant Thomson-Reuters to its Board of Directors. As well as his Board membership, James Smith was appointed to the Corporate Governance and Science and Technology Committees of Pfizer’s Board.
Smith became Reuters’ CEO in January 2012, prior to which he was CEO and Chief Operating Officer (COO) of Thomson Reuters Professional Division. Before the acquisition of Reuters by Thomson, he was COO of Thomson and President and CEO of Thomson Learning’s Academic and Reference Group.
The new board member also serves on the International Business Council of the World Economic Forum, the Board of Directors of the Brazil-US Business Council and the International Advisory Boards of British American Business and the Atlantic Council.
Copyright - Unless otherwise stated all contents of this web site are © 2017 - William Reed Business Media SAS - All Rights Reserved - Full details for the use of materials on this site can be found in the Terms & Conditions
in-PharmaTechnologist presents this month's roundup of who is moving where in the Pharma industry.
Welcome to in-PharmaTechnologist's monthly round up of who's been moving where in the small-molecule manufacturing world. The...
Eli Lilly is conducting several experiments on the International Space Station (ISS) US National Laboratory over the...
The world’s largest modular cGMP biopharmaceutical manufacturing facility came online this week in Wuhan, China.
Valeant, Rentschler, Celgene, MannKind, and Syngene are among those welcoming new leaders for 2016. Oh, and Turing...